某年度美国外用止痛药市场分析报告（PPT 55页）.pptVIP

Market Overview Market Overview 一般情况 Major “Non-Natural Product” OTC Brands主要OTC品牌 Direct Natural Product Competitors: 主要天然产品竞争对手 Tiger Balm Case: Early Disappointment, Later Success 虎牌早期不满意后来较成功的案例 Capsasin Brands Case: Early Success, Later Disappointment 开普莎早期成功，后期不满意 O24 Case: Failure O24 的失败案例 ALCiS Case Conclusion 结论 Market Overview Market Overview Major Non-Natural Product OTC Brands Direct Natural Product Competitors: Tiger Balm Case: Early Disappointment, Later Success Capsasin Brands Case: Early Success, Later Disappointment O24 Case: Failure ALCiS Case Conclusion While the overall OTC and RX pain medication market combined is huge…镇痛药的处方药与OTC 整体市场很大 In 2003, the TOTAL U.S OTC and RX market for pain products was $12 billion： 03年120亿美元 By some measures, the US pain market alone is larger than the entire Chinese pharmaceutical market in 2003 …the market for topical OTC is only $500 M - $700 M 外用OTC药5-7亿美元 However, sales of OTC topical analgesics are estimated to be only $500 -$700 million Prescription products, such as opioids and “NSAIDs” such as COX-2 inhibitors constitute most of the market. 口服的解热镇痛药如非甾抗炎药绝对为主 The market for COX-2’s alone (such as Vioxx and Celebrex) exceeds $5,000,000,000 (RMB 40,000,000,000). 仅环氧化酶2抑制剂药50亿美元 However there is an opportunity for OTC products as the reputation of COX-2s suffers 由于环氧化酶2的声誉正在降低，OTC产品仍有机会 Recent recalls of these prescription medications combined with Qizheng’s efficaciousness in treating pain sufferers may increase the market opportunity. Much of that estimated prescription pain reliever marketplace might be susceptible to penetration by OTC products, such as that of Qizhengs. In addition, the OTC analgesic market is fragmented, there are a few major brands OTC的镇痛药市场分散 In the topical market, Qizheng’s competitors are products such as, but not limited to Ben Gay and Ice Hot, with the total combined market sales estimated to be $250 million in 2002. 奇正的竞争对手除“奔盖”和“冰热”外还有其它许多小品牌 Behind these two market